{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T07:51:14Z","timestamp":1772524274109,"version":"3.50.1"},"reference-count":44,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R24 AI 118397"],"award-info":[{"award-number":["R24 AI 118397"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,7,22]]},"abstract":"<jats:p>Long-acting (LA) administration using a subcutaneous (s.c.) implant presents opportunities to simplify administration of antiretroviral drugs, improve pharmacological profiles, and overcome suboptimal adherence associated with daily oral formulations. Tenofovir alafenamide (TAF) is a highly potent nucleoside reverse transcriptase inhibitor (NRTI) and an attractive agent for LA delivery, with a high potency and long intracellular half-life. The aim of this study was to predict minimum TAF doses required to achieve concentrations effective for HIV preexposure prophylaxis (PrEP).<\/jats:p>","DOI":"10.1128\/aac.00155-20","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T12:54:11Z","timestamp":1589460851000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":12,"title":["Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling"],"prefix":"10.1128","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6015-5712","authenticated-orcid":false,"given":"Rajith K. R.","family":"Rajoli","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zach R.","family":"Demkovich","sequence":"additional","affiliation":[{"name":"RTI International, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Flexner","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Siccardi","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"UNAIDS. 2019. Global HIV & AIDS statistics\u20142019 fact sheet. http:\/\/www.unaids.org\/en\/resources\/fact-sheet. Accessed 1 February 2018."},{"key":"e_1_3_3_3_2","unstructured":"UNAIDS. 2018. The youth bulge and HIV. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/the-youth-bulge-and-hiv_en.pdf. Accessed 21 January 2020."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-018-0408-3"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001555"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2055-6640(20)30312-5","article-title":"How safe is TDF\/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP","volume":"4","author":"Pilkington V","year":"2018","unstructured":"Pilkington V, Hill A, Hughes S, Nwokolo N, Pozniak A. 2018. How safe is TDF\/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP. J Virus Erad 4:215\u2013224.","journal-title":"J Virus Erad"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108524"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200296"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aai9383"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw077"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2019.1612014"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202614"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402269"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000172"},{"key":"e_1_3_3_16_2","unstructured":"Chloe Orkin KA Hern\u00e1ndez-Mora MG Pokrovsky V Overton ET Girard P-M Oka S Ronald D Dorey D Griffith S Margolis DA Williams PE Parys W Spreen W. 2019. Long-acting cabotegravir + rilpivirine for HIV maintenance: FLAIR week 48 results. Conf Retroviruses Opportunistic Infect abstr 140."},{"key":"e_1_3_3_17_2","unstructured":"Susan Swindells J-F-V Richmond GJ Rizzardini G Baumgarten A Del Mar Masia M Latiff G Pokrovsky V Mrus JM Huang JO Hudson KJ Margolis DA Smith K Williams PE Spreen W. 2019. Long-acting cabotegravir + rilpivirine as maintenance therapy: ATLAS week 48 results. Conf Retroviruses Opportunistic Infect abstr 139."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31917-7"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30068-1"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11070315"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.08.010"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00656-15"},{"key":"e_1_3_3_23_2","doi-asserted-by":"crossref","unstructured":"Su JT Simpson SM Sung S Tfaily EB Veazey R Marzinke M Qiu J Watrous D Widanapathirana L Pearson E Peet MM Karunakaran D Grasperge B Dobek G Cain CM Hope T Kiser PF. 2019. A subcutaneous implant of tenofovir alafenamide fumarate causes local inflammation and tissue necrosis in rabbits and macaques. bioRxiv doi:10.1101\/775452.","DOI":"10.1101\/775452"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.11.009"},{"key":"e_1_3_3_25_2","unstructured":"Gilead Sciences. 2019. Gilead statement on commitment to advancing descovy for PrEP\u2122 study in cisgender women & adolescent females."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-018-2513-6"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1227"},{"key":"e_1_3_3_28_2","unstructured":"Jenna Yager KB Castillo-Manchilla J Morrow M Ibrahim M Mchugh C Bushman L Kiser J Mawhinney S Anderson P. Tenofovir-diphosphate in PBMC following increasing TAF vs. TDF dosing under directly observed therapy. http:\/\/regist2.virology-education.com\/presentations\/2019\/20AntiviralPK\/30_Yager.pdf."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2018.0177"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00005-16"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24014"},{"key":"e_1_3_3_32_2","unstructured":"Gatto G Girouard N Brand RM Johnson L Marzinke M Rowshan S Engstrom JC McGowan I Demkovich Z Lueke E van der Straten A. 2018. Pharmacokinetics of tenofovir alafenamide by subcutaneous implant for HIV PREP. Conf Retroviruses Opportunistic Infect abstr 486."},{"key":"e_1_3_3_33_2","first-page":"107","article-title":"Multispecies in vivo evaluation of subdermal implants delivering tenofovir alafenamide: of mice, dogs and sheep","volume":"34","author":"Manjula G","year":"2018","unstructured":"Manjula G, Mariana R-C, Debbie S, Moss JA, Paul W, Chris B, Dana W, Udayan C, Angel G, Joseph K, Gallay PA, Massoud M, Vincent KL, Marzinke MA, Hendrix CW, Baum MM. 2018. Multispecies in vivo evaluation of subdermal implants delivering tenofovir alafenamide: of mice, dogs and sheep. AIDS Res Hum Retroviruses 34:107.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0227-1"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342100-00002"},{"key":"e_1_3_3_36_2","unstructured":"CDC. 2016. Anthropometric reference data for children and adults: United States 2011\u20132014. https:\/\/www.cdc.gov\/nchs\/data\/series\/sr_03\/sr03_039.pdf. Accessed 17 October 2019."},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.3109\/10408444.2012.709225"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0378-5173(99)00147-7"},{"key":"e_1_3_3_39_2","unstructured":"European Medicines Agency. 2016. Assessment report: Vemlidy. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/vemlidy-epar-public-assessment-report_en.pdf. Accessed 4 July 2019."},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847040-00004"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10005"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy726"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001699"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx064"},{"key":"e_1_3_3_45_2","unstructured":"DrugBank. 2019. Tenofovir alafenamide. https:\/\/www.drugbank.ca\/drugs\/DB09299. Accessed 29 July 2019."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00155-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00155-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:41:13Z","timestamp":1645479673000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00155-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,7,22]]}},"alternative-id":["10.1128\/AAC.00155-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.00155-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"assertion":[{"value":"2020-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00155-20"}}